This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Thrombotic microangiopathies (TMAs)

Authoring team

Thrombotic microangiopathies (TMAs)

  • are a group of disorders characterized by thrombocytopaenia, microangiopathic heamolytic anaemia, and ischaemic end-organ damage due to microvascular thrombosis
  • this systemic disorder can affect any organ system, including the brain, heart, and gastrointestinal tract (1)
    • however, the kidney is the most frequently affected organ

Thrombotic microangiopathy is classified as

  • primary
    • including thrombotic thrombocytopenic purpura [TTP] and haemolytic uraemic syndrome [HUS]) or
  • secondary
    • including disseminated intravascular coagulation [DIC],
    • vitamin B12 deficiency,
    • autoimmune diseases,
    • uncontrolled hypertension,
    • infections, medications,
    • malignancies
      • in cancer patients, TMA can arise from
        • (1) the cancer itself (cancer-associated TMA),
        • (2) cancer treatments, or
        • (3) unrelated causes
      • may be the first sign of undiagnosed cancer, but it is more frequently seen during the progression of known metastatic cancer (2)

Reference:

  1. Jalal A, Atari M, Hassanein M, et al. Thrombotic Microangiopathy and the Kidney. [Updated 2025 Mar 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
  2. Sullivan CM et al. Breast Cancer–Associated Thrombotic Microangiopathy: The Paradox of Stable Scans and Unstable Blood. AIM Clinical Cases.2025;4:e250421.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.